CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX110™ for the Treatment of Relapsed or Refractory CD19+ B-cell malignancies

Daniel Sontupe
Market Access

Bud Bilanich
Success Coach

Paul Theisen
Patient Acquisition

Stacey Gandler
Brand Nourishment

David Linetsky
Point-of-Care Marketing

Amy Giles
Increasing Engagement

Pat Purcell
Meeting Engagement

Liz Kane
Impactful Strategy

Matthew Durham
Omnidynamic Marketing

Brenda Snow
Authentic Patient Voice

Suma Ramadas, PhD
Medical Affairs

Frank Burrell
Scientific Storytelling

Matt Turner
Patient Affordability

Joey Cohen
Medication Adherence